
Drug-Eluting Stents
Description
Global Drug-Eluting Stents Market to Reach US$11.7 Billion by 2030
The global market for Drug-Eluting Stents estimated at US$8.3 Billion in the year 2024, is expected to reach US$11.7 Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. Polymer-Free, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$7.9 Billion by the end of the analysis period. Growth in the Polymer-based segment is estimated at 5.2% CAGR over the analysis period.
The U.S. Market is Estimated at US$2.2 Billion While China is Forecast to Grow at 9.5% CAGR
The Drug-Eluting Stents market in the U.S. is estimated at US$2.2 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 9.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.
strong>Global Drug-Eluting Stents Market - Key Trends and Drivers Summarized
What Are Drug-Eluting Stents and How Do They Function?
Drug-eluting stents (DES) are specialized medical devices used to treat coronary artery disease (CAD), a condition characterized by the narrowing of coronary arteries due to plaque buildup. These stents are tiny mesh tubes coated with medication that is gradually released to prevent the artery from becoming blocked again, a process known as restenosis. The structure of a drug-eluting stent includes a metal scaffold to provide mechanical support to the artery, and a polymer coating that controls the release of the drug over time. The drug inhibits cell proliferation and reduces inflammation, which are critical factors in preventing restenosis. By combining mechanical and pharmacological approaches, DES offer a significant improvement over bare-metal stents (BMS), which only provide structural support and are associated with higher rates of restenosis.
How Have Technological Advancements Improved Drug-Eluting Stents?
The field of drug-eluting stents has seen remarkable technological advancements that have enhanced their efficacy and safety profiles. Innovations in stent design, such as thinner struts and more flexible materials, have improved the deliverability and conformability of the stents, allowing for easier navigation through complex arterial pathways. The development of biodegradable polymers, which gradually dissolve after delivering the drug, has reduced long-term complications associated with permanent polymer residues. Advances in drug formulations have also played a crucial role, with newer drugs offering better control over cell proliferation and inflammation. Imaging technologies, such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT), have further refined the deployment process by providing real-time, high-resolution images of the arteries, ensuring precise placement and optimal expansion of the stents. These technological improvements collectively contribute to better patient outcomes, reducing the incidence of adverse events and the need for repeat interventions.
What Are the Clinical Applications and Benefits of Drug-Eluting Stents?
Drug-eluting stents are primarily used in the treatment of coronary artery disease, but their applications extend to other vascular conditions as well. They are employed in the management of peripheral artery disease (PAD), where they help to open narrowed arteries in the legs, enhancing blood flow and reducing symptoms like pain and fatigue. The use of DES in treating complex lesions, such as those in patients with diabetes or multivessel disease, has shown promising results, offering a safer and more effective alternative to surgical interventions. The primary benefits of DES include a lower risk of restenosis and reduced need for repeat revascularization procedures, leading to improved long-term patient outcomes. Additionally, the minimally invasive nature of stent implantation, combined with shorter hospital stays and faster recovery times compared to open-heart surgery, makes DES a preferred option for many patients and healthcare providers.
What Drives the Growth in the Drug-Eluting Stents Market?
The growth in the drug-eluting stents market is driven by several factors, including technological advancements, increasing prevalence of cardiovascular diseases, and expanding healthcare infrastructure. The rising incidence of coronary artery disease, partly due to lifestyle changes and an aging population, is significantly boosting the demand for effective treatment options like DES. Advances in stent technology, such as the development of next-generation stents with enhanced biocompatibility and drug delivery mechanisms, are propelling market growth. Additionally, the growing preference for minimally invasive procedures among patients and healthcare providers is driving the adoption of DES over traditional surgical methods. Regulatory approvals and favorable reimbursement policies are also playing a crucial role in expanding the market reach. Furthermore, increasing investments in research and development by key industry players and the expansion of healthcare facilities in emerging markets are creating new opportunities for growth. The integration of advanced imaging technologies with stent deployment procedures is improving clinical outcomes, further strengthening the case for DES in cardiovascular treatment protocols. These factors, combined with a greater awareness of heart health and proactive management of cardiovascular conditions, are driving the robust growth of the drug-eluting stents market.
SCOPE OF STUDY:The report analyzes the Drug-Eluting Stents market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Coating (Polymer-Free, Polymer-based); Application (Coronary Artery Disease, Peripheral Artery Disease); End-Use (Cardiology Centers, Ambulatory Surgery Centers, Hospitals)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 33 Featured) -
- Abbott Laboratories
- AlviMedica
- Arterius Limited
- Biotronik SE
- Boston Scientific Corporation
- Cook Medical
- Medtronic plc
- STENTYS SA
- Terumo Corporation
We`re transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Table of Contents
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- Global Economic Update
- Drug-Eluting Stents – Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Technological Advancements in Stent Design Propel Growth in Drug-Eluting Stents Market
- Increasing Prevalence of Cardiovascular Diseases Expands Addressable Market Opportunity
- Innovations in Biodegradable Polymers Strengthen Business Case for Next-Generation Stents
- Advances in Drug Formulations Enhance Efficacy and Reduce Complications
- Growing Geriatric Population Generates Increased Demand for Cardiovascular Treatments
- Trends in Personalized Medicine and Patient-Specific Solutions Propel Market Growth
- Expansion of Healthcare Infrastructure in Emerging Markets Creates New Opportunities
- Integration of Imaging Technologies and Stent Deployment Techniques Improves Outcomes
- Focus on Long-Term Patient Outcomes and Reduced Restenosis Rates Sustains Growth
- Adoption of Advanced Manufacturing Processes Enhances Stent Quality and Performance
- Development of Dual Therapy Stents and Combination Products Generates New Market Segments
- Impact of Lifestyle Changes and Risk Factors on Cardiovascular Health Drives Market Demand
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Drug-Eluting Stents Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Drug-Eluting Stents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Drug-Eluting Stents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 4: World 15-Year Perspective for Drug-Eluting Stents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Polymer-Free by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Polymer-Free by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 7: World 15-Year Perspective for Polymer-Free by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Polymer-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Polymer-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 10: World 15-Year Perspective for Polymer-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Coronary Artery Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Coronary Artery Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 13: World 15-Year Perspective for Coronary Artery Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Peripheral Artery Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Peripheral Artery Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 16: World 15-Year Perspective for Peripheral Artery Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Cardiology Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 18: World Historic Review for Cardiology Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 19: World 15-Year Perspective for Cardiology Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 20: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 21: World Historic Review for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 22: World 15-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 23: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 24: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 25: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- III. MARKET ANALYSIS
- UNITED STATES
- Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 26: USA Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 27: USA Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 28: USA 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 29: USA Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 30: USA Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 31: USA 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 32: USA Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 33: USA Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 34: USA 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- CANADA
- TABLE 35: Canada Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 36: Canada Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 37: Canada 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 38: Canada Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: Canada Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 40: Canada 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 41: Canada Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: Canada Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 43: Canada 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- JAPAN
- Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 44: Japan Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: Japan Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 46: Japan 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 47: Japan Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: Japan Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 49: Japan 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 50: Japan Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: Japan Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 52: Japan 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- CHINA
- Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 53: China Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 54: China Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 55: China 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 56: China Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: China Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 58: China 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 59: China Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: China Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 61: China 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- EUROPE
- Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 62: Europe Recent Past, Current & Future Analysis for Drug-Eluting Stents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 63: Europe Historic Review for Drug-Eluting Stents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 64: Europe 15-Year Perspective for Drug-Eluting Stents by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 65: Europe Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: Europe Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 67: Europe 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 68: Europe Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: Europe Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 70: Europe 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 71: Europe Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 72: Europe Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 73: Europe 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- FRANCE
- Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 74: France Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: France Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 76: France 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 77: France Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 78: France Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 79: France 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 80: France Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: France Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 82: France 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- GERMANY
- Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 83: Germany Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: Germany Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 85: Germany 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 86: Germany Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: Germany Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 88: Germany 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 89: Germany Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 90: Germany Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 91: Germany 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- ITALY
- TABLE 92: Italy Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: Italy Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 94: Italy 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 95: Italy Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 96: Italy Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 97: Italy 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 98: Italy Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Italy Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 100: Italy 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- UNITED KINGDOM
- Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 101: UK Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 102: UK Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 103: UK 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 104: UK Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 105: UK Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 106: UK 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 107: UK Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: UK Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 109: UK 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- SPAIN
- TABLE 110: Spain Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 111: Spain Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 112: Spain 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 113: Spain Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 114: Spain Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 115: Spain 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 116: Spain Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 117: Spain Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 118: Spain 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- RUSSIA
- TABLE 119: Russia Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 120: Russia Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 121: Russia 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 122: Russia Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 123: Russia Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 124: Russia 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 125: Russia Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 126: Russia Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 127: Russia 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- REST OF EUROPE
- TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 129: Rest of Europe Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 130: Rest of Europe 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 132: Rest of Europe Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 133: Rest of Europe 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 135: Rest of Europe Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 136: Rest of Europe 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- ASIA-PACIFIC
- Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Drug-Eluting Stents by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 138: Asia-Pacific Historic Review for Drug-Eluting Stents by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 139: Asia-Pacific 15-Year Perspective for Drug-Eluting Stents by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
- TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 141: Asia-Pacific Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 142: Asia-Pacific 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 144: Asia-Pacific Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 145: Asia-Pacific 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 147: Asia-Pacific Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 148: Asia-Pacific 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- AUSTRALIA
- Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 149: Australia Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 150: Australia Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 151: Australia 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 152: Australia Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 153: Australia Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 154: Australia 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 155: Australia Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 156: Australia Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 157: Australia 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- INDIA
- Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 158: India Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 159: India Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 160: India 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 161: India Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 162: India Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 163: India 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 164: India Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 165: India Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 166: India 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- SOUTH KOREA
- TABLE 167: South Korea Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 168: South Korea Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 169: South Korea 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 170: South Korea Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 171: South Korea Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 172: South Korea 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 173: South Korea Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 174: South Korea Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 175: South Korea 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- REST OF ASIA-PACIFIC
- TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 177: Rest of Asia-Pacific Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 178: Rest of Asia-Pacific 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 180: Rest of Asia-Pacific Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 183: Rest of Asia-Pacific Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- LATIN AMERICA
- Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 185: Latin America Recent Past, Current & Future Analysis for Drug-Eluting Stents by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 186: Latin America Historic Review for Drug-Eluting Stents by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 187: Latin America 15-Year Perspective for Drug-Eluting Stents by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
- TABLE 188: Latin America Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 189: Latin America Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 190: Latin America 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 191: Latin America Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 192: Latin America Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 193: Latin America 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 194: Latin America Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 195: Latin America Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 196: Latin America 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- ARGENTINA
- TABLE 197: Argentina Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 198: Argentina Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 199: Argentina 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 200: Argentina Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 201: Argentina Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 202: Argentina 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 203: Argentina Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 204: Argentina Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 205: Argentina 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- BRAZIL
- TABLE 206: Brazil Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 207: Brazil Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 208: Brazil 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 209: Brazil Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 210: Brazil Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 211: Brazil 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 212: Brazil Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 213: Brazil Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 214: Brazil 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- MEXICO
- TABLE 215: Mexico Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 216: Mexico Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 217: Mexico 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 218: Mexico Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 219: Mexico Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 220: Mexico 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 221: Mexico Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 222: Mexico Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 223: Mexico 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- REST OF LATIN AMERICA
- TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 225: Rest of Latin America Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 226: Rest of Latin America 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 228: Rest of Latin America Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 229: Rest of Latin America 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 231: Rest of Latin America Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 232: Rest of Latin America 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- MIDDLE EAST
- Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 233: Middle East Recent Past, Current & Future Analysis for Drug-Eluting Stents by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 234: Middle East Historic Review for Drug-Eluting Stents by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 235: Middle East 15-Year Perspective for Drug-Eluting Stents by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
- TABLE 236: Middle East Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 237: Middle East Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 238: Middle East 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 239: Middle East Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 240: Middle East Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 241: Middle East 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 242: Middle East Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 243: Middle East Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 244: Middle East 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- IRAN
- TABLE 245: Iran Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 246: Iran Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 247: Iran 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 248: Iran Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 249: Iran Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 250: Iran 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 251: Iran Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 252: Iran Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 253: Iran 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- ISRAEL
- TABLE 254: Israel Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 255: Israel Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 256: Israel 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 257: Israel Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 258: Israel Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 259: Israel 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 260: Israel Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 261: Israel Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 262: Israel 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- SAUDI ARABIA
- TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 264: Saudi Arabia Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 265: Saudi Arabia 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 267: Saudi Arabia Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 268: Saudi Arabia 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 270: Saudi Arabia Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 271: Saudi Arabia 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- UNITED ARAB EMIRATES
- TABLE 272: UAE Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 273: UAE Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 274: UAE 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 275: UAE Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 276: UAE Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 277: UAE 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 278: UAE Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 279: UAE Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 280: UAE 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- REST OF MIDDLE EAST
- TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 282: Rest of Middle East Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 283: Rest of Middle East 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 285: Rest of Middle East Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 286: Rest of Middle East 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 288: Rest of Middle East Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 289: Rest of Middle East 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- AFRICA
- Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 290: Africa Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 291: Africa Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 292: Africa 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
- TABLE 293: Africa Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 294: Africa Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 295: Africa 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
- TABLE 296: Africa Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 297: Africa Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 298: Africa 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
- IV. COMPETITION
Pricing
Currency Rates